The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals
试验速览
- 阶段
- 4 期
- 入组人数
- 84
- 试验地点
- 1
- 主要终点
- Serum SGOT concentrations
研究概览
简要总结
In this double blind placebo controlled trial,cytokine secretion of CD4+ T-cells after 4 month supplementation of vitamin A will be compared with placebo intaking group.
详细描述
Obesity is a chronic disease consisting of the increase in body fat stores. Obesity is an important health concern because of its well known relationships with metabolic and endocrine disorders such as cardiovascular disease, type 2 diabetes, hypertension and immune dysfunction. Low-grade systemic inflammation, confirmed by the increase of inflammatory markers such as C-reactive protein and interleukin-6 has been observed in obesity. CD4+ T-helpers are the most important regulators of immune system. Epidemiological evidence has linked obesity to several (but not all) autoimmune disorders, including inflammatory bowel disease (IBD) and psoriasis .Some sublineages of T- helpers plays core roles in immune dysfunction, and recent evidence demonstrates that an imbalance of T-cell subgroups including Th1, Th2, Th17 and Treg has occurred in obesity. This imbalance is the redirection of the immune response from most often Th2 and Treg like responses to Th1 and Th17 like responses respectively, however the opposite is desired. Vitamin A (VA) or VA-like analogs known as retinoids, are potent hormonal modifiers of type 1 or type 2 responses but a definitive description of their mechanism(s) of action is lacking. High level dietary vitamin A enhances Th2 cytokine production and IgA responses, and is likely to decrease Th1 cytokine production. Retinoic acid inhibits IL-12 production in activated macrophages, and RA pretreatment of macrophages reduces IFNγ and TNF α production and increases IL4 production in antigen primed CD4 T cells. Supplemental treatment with vitamin A or retinoic acid (RA) decreases IFNγ and increases IL5, IL10, and IL4 production.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 52 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •waist to hip ratio >0.8 and BMI>30 kg/m2 for obese individuals waist to hip ratio <0.8 and BMI 18.5 - 24.9 kg/m2 for Non obese individuals
排除标准
- •subjects who have diseases which affect on Th1/Th2 balance such as asthma, active viral infections, and autoimmune diseases, OR
- •subjects with pregnancy, lactation, menopause, diabetes
- •subjects who have allergy to vitamin A compounds, OR
- •subjects who have used vitamin supplements or in last 3 months, OR
- •subjects with morbid obesity(BMI >40 kg/m2),OR
- •overweight subjects (25 <BMI<29.9 kg/m2)
结局指标
主要结局
Serum SGOT concentrations
时间窗: Change from baseline at 4 months
Serum SGPT concentrations
时间窗: Change from baseline at 4 months
Complete Blood Count-diff
时间窗: Change from baseline at 4 months
Serum HDL concentrations
时间窗: Change from baseline at 4 months
Serum LDL concentrations
时间窗: Change from baseline at 4 months
Serum total cholesterol concentrations
时间窗: Change from baseline at 4 months
Serum Triglycerides concentrations
时间窗: Change from baseline at 4 months
Serum T3 concentrations
时间窗: Change from baseline at 4 months
Serum T4 concentrations
时间窗: Change from baseline at 4 months
Serum TSH concentrations
时间窗: Change from baseline at 4 months
Serum FBS concentrations
时间窗: Change from baseline at 4 months
Serum CRP concentrations
时间窗: Change from baseline at 4 months
Serum RF concentrations
时间窗: Change from baseline at 4 months
次要结局
- Serum TGF β concentrations(Change from baseline at 4 months)
- serum IFN γ concentrations(Change from baseline at 4 months)
- serum Angiotensin П concentrations(Change from baseline at 4 months)
- Serum IL-2 concentrations(Change from baseline at 4 months)
- Serum IL-6 concentrations(Change from baseline at 4 months)
- Serum IL-10 concentrations(Change from baseline at 4 months)
- Serum IL-12 concentrations(Change from baseline at 4 months)
- Serum IL-13 concentrations(Change from baseline at 4 months)
- Serum IL-17 concentrations(Change from baseline at 4 months)
- Seum IL-1β concentrations(Change from baseline at 4 months)
